Assessment of Effect of Rapastinel on Driving Performance
Brief Summary
Based on the pharmacological class of rapastinel, this study will be conducted to evaluate the participant's driving performance after single IV doses of rapastinel as compared with single oral doses of alprazolam, a benzodiazepine that demonstrates driving impairment, and placebo in healthy participants.
Intervention / Treatment
-
Drug: Rapastinel
-
Drug: Alprazolam
-
Drug: Ketamine
-
Drug: Rapastinel Matched Placebo
-
Drug: Alprazolam Matched Placebo
-
Drug: Ketamine Matched Placebo
Condition or Disease
- Driving Performance
Phase
Study Design
| Study type: | Interventional |
|---|---|
| Status: | Completed |
| Study results: | No Results Available |
| Age: | 21 Years to 65 Years (Adult, Older Adult) |
| Enrollment: | 107 () |
| Funded by: | Industry |
Masking |
|
Clinical Trial Dates
| Start date: | Nov 05, 2018 | |
|---|---|---|
| Primary Completion: | Mar 29, 2019 | |
| Completion Date: | Apr 03, 2019 | |
| Study First Posted: | Jan 24, 2019 | |
| Results First Posted: | Aug 31, 2020 | |
| Last Updated: | Jul 11, 2019 |
Sponsors / Collaborators
Lead Sponsor:
N/A
Responsible Party:
N/A
Eligibility Criteria
| Sex: | All |
|---|---|
| Minimum Age: | 21 |
| Maximum Age: | 65 |
More Details
| NCT Number: | NCT03814733 |
|---|---|
| Other IDs: | RAP-PK-18 |
| Study URL: | https://ClinicalTrials.gov/show/NCT03814733 |
Last updated: Jan 27, 2021